Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Esophageal Cancer Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

106 recruiting trials for Esophageal Cancer. Eligibility criteria explained in plain English.

TrialFinderData lists 106 Esophageal Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 42% (25 studies); the largest phase groups are Phase 2: 25, Phase 1: 12, Phase 1 / Phase 2: 10, Phase 3: 9.

Research is led by Sun Yat-sen University (4), Fudan University (4), Sichuan University (3), among the most active sponsors registered for these trials.

The most frequently studied intervention is Cisplatin (drug, 7 trials), followed by Paclitaxel, Radiotherapy.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
106
Total Trials
106
Recruiting Now
9
Phase 3 Trials
10
Sponsors

Track Esophageal Cancer trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 4NCT05183126

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the...

Sponsor: University of Michigan Rogel Cancer CenterEnrolling: 221 location
RECRUITINGNCT02838836

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery....

Sponsor: University of Missouri-ColumbiaEnrolling: 6201 location
RECRUITINGNCT03787056

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric...

Sponsor: Hospices Civils de LyonEnrolling: 41017 locations
RECRUITINGPhase 1 / Phase 2NCT06298916

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and...

Sponsor: Lantheus Medical ImagingEnrolling: 265 locations
RECRUITINGPhase 1NCT06910657

IDOV-Immune for Advanced Solid Tumors

This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not...

Sponsor: ViroMissile, Inc.Enrolling: 786 locations
RECRUITINGNCT06101277

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid...

Sponsor: University of California, DavisEnrolling: 3001 location
RECRUITINGPhase 1NCT06673329

Brodalumab in the Treatment of Immune-Related Adverse Events

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects...

Sponsor: Brian Henick, MDEnrolling: 111 location
RECRUITINGNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer...

Sponsor: Adela, IncEnrolling: 700017 locations
RECRUITINGNCT01048281

Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

Our research of the biology of upper gastrointestinal cancers involves the study of tissue samples and cells from biopsies of persons with gastric or esophageal cancer or blood...

Sponsor: Stanford UniversityEnrolling: 1001 location
RECRUITINGPhase 3NCT07431281

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or...

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L)...

Sponsor: AstraZenecaEnrolling: 213020 locations
RECRUITINGPhase 3NCT06022861

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced...

This is a randomized, double-blind, multicenter, Phase 3 study to compare the efficacy and safety of LY01015 and Opdivo®(Nivolumab Injection)combined respectively with...

Sponsor: Shandong Boan Biotechnology Co., LtdEnrolling: 5101 location
RECRUITINGNCT04117100

Advanced Endo-therapeutic Procedure : Registry-based Observational Study

Advanced therapeutic endoscopy procedures are of increasing importance to provide minimal invasive treatment for GI diseases. The Centre Hospitalier de l'Université de Montréal as...

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)Enrolling: 5001 location
RECRUITINGPhase 2NCT07282912

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With...

This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with...

Sponsor: Yale UniversityEnrolling: 541 location
RECRUITINGNCT07043491

Comparison of Endoscopy and Esophagram for the Routine Evaluation of Anastomosis After McKeown Esophagectomy

This retrospective cohort study reviewed patients who underwent McKeown esophagectomy. All patients routinely underwent either endoscopy or esophagram for the evaluation of...

Sponsor: Sun Yat-sen UniversityEnrolling: 21 location
RECRUITINGPhase 2NCT06422403

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab,...

Sponsor: National University Hospital, SingaporeEnrolling: 3601 location
RECRUITINGPhase 1 / Phase 2NCT05910827

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers

Sponsor: Hummingbird BioscienceEnrolling: 39820 locations
RECRUITINGNCT00260585

Esophageal Cancer Risk Registry

The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research...

Sponsor: University of PittsburghEnrolling: 70001 location
RECRUITINGNCT06961526

Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

The goal of this prospective cohort study is to evaluate the progression of esophagogastric varices in patients treated with atezolizumab-bevacizumab. Assess the efficacy of...

Sponsor: Tanta UniversityEnrolling: 1101 location
RECRUITINGPhase 2NCT06663059

Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

Observing the efficacy and safety of 2 cycles versus 4 cycles of Adebrelimab combined with chemotherapy as neoadjuvant treatment for patients with resectable locally advanced...

Sponsor: Tang-Du HospitalEnrolling: 801 location
RECRUITINGNCT07660627

Determining Minimal Residual Disease Using ctDNA Deep Sequencing

Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early...

Sponsor: Masaryk Memorial Cancer InstituteEnrolling: 341 location
RECRUITINGPhase 1NCT06545331

Study of XB010 in Subjects With Solid Tumors

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with...

Sponsor: ExelixisEnrolling: 39620 locations
RECRUITINGNCT06618742

Focal Cryoballoon Ablation for Malignant Dysphagia

Rationale: Dysphagia is commonly encountered in patients with esophageal carcinoma who are no candidates for treatment with curative intent. It often has a considerable impact on...

Sponsor: Laura BoerEnrolling: 201 location
RECRUITINGNCT03835273

Oesophagectomy and Chest Wall and Respiratory Function

Open surgery for esophageal cancer commonly involves large incisions in the chest, associated with a high rate of pulmonary complications (30-50%). Minimally invasive approach...

Sponsor: Imperial College LondonEnrolling: 1001 location
RECRUITINGNCT07272382

Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer

This is a randomized, double-blind, placebo-controlled phase II clinical trial designed to evaluate whether adding omega-3 fatty acids improves outcomes in adult patients with...

Sponsor: Fudan UniversityEnrolling: 1421 location
RECRUITINGPhase 2 / Phase 3NCT06721520

Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy

The goal of this pragmatic, registry-based, randomized clinical trial is to find out if using botulinum toxin (Botox) to help drain the stomach during an esophagectomy works as...

Sponsor: The Cleveland ClinicEnrolling: 1701 location
RECRUITINGEarly Phase 1NCT06828588

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who...

Sponsor: Vanderbilt-Ingram Cancer CenterEnrolling: 301 location
RECRUITINGNCT00590239

Barrett's Esophagus Related Neoplasia (BERN) Project

* The use of high resolution endoscopy (HRE), narrow band imaging (NBI) and chromoendoscopy increases the detection rates of Barrett's esophagus (BE) and early neoplasia. *...

Sponsor: Midwest Biomedical Research FoundationEnrolling: 1501 location
RECRUITINGNCT05642338

A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS)...

The investigators aim to study the rate of developing a biopsy-based diagnosis of high-grade dysplasia (HGD) and EAC in BE patients in a prospective cohort of 208 BE patients at...

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Enrolling: 4161 location
RECRUITINGNCT04510129

A Multicenter Cancer Biospecimen Collection Study

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor...

Sponsor: Cofactor Genomics, Inc.Enrolling: 16501 location
RECRUITINGPhase 1 / Phase 2NCT05944237

HTL0039732 in Participants With Advanced Solid Tumours

The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other...

Sponsor: Cancer Research UKEnrolling: 1505 locations
RECRUITINGPhase 1NCT07544589

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric...

Sponsor: Dispatch BiotherapeuticsEnrolling: 663 locations
RECRUITINGNCT06070376

Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.

Esophageal cancer is the seventh most common type of cancer in the world, with an estimated global incidence of 604,100 new cases per year. The main symptom of esophageal cancer...

Sponsor: Instituto do Cancer do Estado de São PauloEnrolling: 341 location
RECRUITINGPhase 2NCT06165380

Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

The goal of this trial is to test the efficacy and safety of cardenilimab combined with chemotherapy in the conversion therapy of locally advanced unresectable esophageal squamous...

Sponsor: Li ZhangEnrolling: 431 location
RECRUITINGPhase 1NCT06623396

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 187 locations
RECRUITINGPhase 2NCT07039162

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

This is a Phase II, open-label, single-arm, multicenter study evaluating the safety and efficacy of combining Tislelizumab with induction chemoradiotherapy (CRT), followed by...

Sponsor: Ming-Yu LienEnrolling: 458 locations
RECRUITINGPhase 2NCT07152678

Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma

The goal of this clinical trial is to learn if adding high-dose-rate (HDR) brachytherapy can improve outcomes in patients with locally advanced esophageal squamous cell carcinoma...

Sponsor: National Taiwan University HospitalEnrolling: 601 location
RECRUITINGPhase 3NCT04821778

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy,...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 20005 locations
RECRUITINGPhase 1 / Phase 2NCT04278287

Chemoradiotherapy in Unresectable Esophageal Cancer

This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 1055 locations
RECRUITINGNCT03948100

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small...

This trial studies how well dyadic yoga intervention works in improving physical performance and quality of life in patients with stage I-IV non-small cell lung or esophageal...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 4001 location
RECRUITINGPhase 2NCT07519486

Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC

Malnutrition is highly prevalent in patients with upper gastrointestinal tumors, which may negatively impact treatment tolerance and anti-tumor immune responses. This study aims...

Sponsor: Sichuan UniversityEnrolling: 1181 location
RECRUITINGPhase 2NCT07638436

Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell...

This clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for...

Sponsor: Sun Yat-sen UniversityEnrolling: 421 location
RECRUITINGNCT07264036

Velopharyngeal Dysfunction in Head & Neck Cancer Patients, Pilot Study

Some head and neck cancer survivors develop velopharyngeal dysfunction (VPD), a problem with closure between the soft palate and throat that can cause nasal-sounding speech, food...

Sponsor: Vanessa TorrecillasEnrolling: 201 location
RECRUITINGPhase 2NCT04939051

Obeticholic Acid for Prevention in Barrett's Esophagus

This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to...

Sponsor: National Cancer Institute (NCI)Enrolling: 308 locations
RECRUITINGPhase 2NCT05515315

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally...

To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)

Sponsor: Fuzhou General HospitalEnrolling: 931 location
RECRUITINGNCT06393140

The Study on the Mechanism of Radiotherapy-elicited Immune Response

Radiotherapy plays an important role in multidisciplinary treatment of esophageal cancer. Data from many laboratories indicate that local radiation produces systemic,...

Sponsor: Fudan UniversityEnrolling: 2001 location
RECRUITINGNCT00991094

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 50001 location
RECRUITINGPhase 2NCT07086469

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With...

The combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further...

Sponsor: Sun Yat-sen UniversityEnrolling: 691 location
RECRUITINGPhase 3NCT05919030

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced...

This study is a multicentre, randomised, parallel-controlled, open-label, 3 phase clinical trial. The subjects were untreated, unresectable locally advanced, recurrent or...

Sponsor: Renmin Hospital of Wuhan UniversityEnrolling: 1551 location
RECRUITINGPhase 2NCT06846346

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

The goal of this clinical trial is to evaluate the addition of ivonescimab to standard chemotherapy in patients with advanced or metastatic gastric and gastroesophageal...

Sponsor: UNICANCEREnrolling: 884 locations
RECRUITINGPhase 2NCT05332002

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical...

Sponsor: Rutgers, The State University of New JerseyEnrolling: 386 locations

Showing 50 of 106 trials.Search all Esophageal Cancer trials

Frequently Asked Questions

There are currently 106 clinical trials for Esophageal Cancer, with 106 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Esophageal Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 9 Phase 3 trials for Esophageal Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.